 Ocular Therapeutix Inc NASDAQ: OCUL announced topline results from its Phase 2 trial of OTX-DED dexamethasone intracanalicular ophthalmic insert for the short-term treatment of dry eye disease. The clinical trial achieved its pre-specified primary endpoint, demonstrating a statistically significant change of bulbar conjunctival hyperemia from baseline to day 15 compared to vehicle hydrogel. 